Keystone Nano wins FDA nod for nanoliposome cancer treatment

Keystone Nano said today that the FDA approved its investigational new drug application for the ceramide nanoliposome as a treatment for solid tumors. The company will launch a phase I trial at 3 sites to evaluate safe dosing levels and the product’s efficacy as a cancer therapy. Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that Keystone’s nanoliposome is an effective delivery system for the bioactive compound, targeting cancer cells and ignoring healthy cells. Get the full story at our sister site, Drug Delivery Business News. The post Keystone Nano wins FDA nod for nanoliposome cancer treatment appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Oncology Pharmaceuticals Regulatory/Clearance Wall Street Beat Keystone Nano Source Type: news

Related Links:

CONCLUSION: Targeting critical ribosome biogenesis components in order to decrease the genotoxic activity in cancer cell looks promising. Hence, we believe that targeting key protein rRNA methyltransferase FBL shows great potential, due to its pivotal role in ribosome biogenesis, its correlation to an improved survival rate at low expression in breast cancer patients and its association with p53. PMID: 30501594 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
The dream about a drop of blood signaling a wide range of diagnostic results was shattered with Elizabeth Holmes and the Theranos scam. The machination of the company has set back the innovation of blood testing and investment into the field for years. However, there’s always hope. The Medical Futurist looked around where blood testing stands today and what’s the future it is heading towards. Dreaming about a home laboratory Stephen just came home from walking his dog, Barney, an always smiling labrador. The 40-something got off his smart shoes, sat back on the yellow couch that he and her partner, Sara, were f...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Biotechnology Business Future of Medicine Medical Professionals Patients Portable Diagnostics Researchers blood blood draw blood test blood testing digital health health market home Innovation laboratory theranos Source Type: blogs
Thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering (MSK) Cancer Center believes customized gene therapy will soon change the way pleural mesothelioma is treated. Adusumilli, director of the Mesothelioma Program at MSK, has worked for a decade on developing tumor immunology for thoracic malignancies. He is currently the principal investigator of a phase I clinical trial involving specially prepared immune cells — chimeric antigen receptor (CAR) T cells — that have shown impressive efficacy with mesothelioma. “I think this is going to change the paradigm of treating mesotheliom...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Alexander W Abstract We review key findings in the areas of prostate cancer, non-small-cell lung cancer, breast cancer, esophageal cancer, pancreatic cancer, leukemias, metastatic colon cancer, and one session on molecular profiling guidance of therapy. PMID: 30100691 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
Cachexia is a multifactorial and multi-organ syndrome that is one of the main causes of morbidity and mortality in late stages of chronic conditions such as AIDS, chronic obstructive pulmonary disease (COPD), congestive heart failure, multiple sclerosis, tuberculosis, and cancer. More than 50 percent of cancer patients suffer from cachexia at death, with the distribution varying by tumor type; the incidence is highest in patients with gastric and pancreatic cancer ( ∼80%) while patients with breast cancer and leukemia demonstrate the lowest frequency (∼40%) of affliction with cachexia (Argiles et al., 2005; Muscari...
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research
ConclusionWe predicted continuing falls in mortality rates from major cancer sites in the EU and its major countries to 2018. Exceptions are pancreatic cancer and lung cancer in women. Improved treatment and —above age 50 years—organized screening may account for recent favourable colorectal cancer trends.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Excerpted fromPrecision Medicine and the Reinvention of Human DiseaseDespite having the most advanced healthcare technology on the planet, life expectancy in the United States is not particularly high. Citizens from most of the European countries and the highly industrialized Asian countries enjoy longer life expectancies than the United States. According to the World Health Organization, the United States ranks 31st among nations, trailing behind Greece, Chile, and Costa Rica, and barely edging out Cuba [42]. Similar rankings are reported by the US Central Intelligence Agency [43]. These findings lead us to infer that acc...
Source: Specified Life - Category: Information Technology Tags: cancer cancer vaccines precision medicine prevention public health Source Type: blogs
Publication date: Available online 31 January 2018 Source:The Lancet Author(s): Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of ...
Source: The Lancet - Category: General Medicine Source Type: research
Purpose of review Germline pathogenic TP53 mutation may predispose to multiple cancers but penetrance and cancer patterns remain incompletely documented. We have analyzed international agency for research on cancer TP53 database to reevaluate age and variant-dependent tumor patterns. Recent findings Genome-wide studies suggest that germline variants are more frequent than estimated prevalence of Li–Fraumeni syndrome (LFS), suggesting that many carriers of potentially pathogenic mutations may not develop the syndrome. Carriers of a germline TP53 mutation who are detected in a clinical context have a penetrance of...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: CANCER BIOLOGY: Edited by Pierre Hainaut Source Type: research
Abstract Paradoxically, trichothecenes have both immunosuppressive and immunostimulatory effects. The underlying mechanisms have not been fully explored. Early studies show that dose, exposure timing, and the time at which immune function is assessed influence whether trichothecenes act in an immunosuppressive or immunostimulatory fashion. Recent studies suggest that the immunomodulatory function of trichothecenes is also actively shaped by competing cell-survival and death-signaling pathways. Autophagy may also promote trichothecene immunosuppression, although the mechanism may be complicated. Moreover, trichothe...
Source: Archives of Toxicology - Category: Toxicology Authors: Tags: Arch Toxicol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Investigational New Drugs | Leukemia | Liver | Nanotechnology | New Drug Applications | Pancreas | Pancreatic Cancer | Urology & Nephrology